Despite evidence supporting the benefits of ACE inhibitors, ARBs, and SGLT2 inhibitors, providers’ prescription patterns for patients with diabetic kidney disease are not aligned with guideline standards, and current prescription rates of these renoprotective drugs are low in type 2 diabetes mellitus patients who could benefit from these medications [8, 9, 11–14]. This evidence concerns the gene ACE and diabetic kidney disease.